New drug combo may slash heart attacks in high-risk patients

NCT ID NCT06863545

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a powerful cholesterol-lowering drug (PCSK9 inhibitor) to standard treatment can prevent heart attacks, strokes, and death in people with high-risk coronary plaques seen on CT scans. About 3,600 adults with at least one severely narrowed or high-risk plaque will be followed to compare outcomes. The goal is to see if the extra medication offers better protection than standard therapy alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR EVENTS CORONARY ARTERY DISEASE CT ANGIOGRAPHY PCSK9

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hangzhou Linping First People's Hospital
RECRUITING

Hangzhou, China

Contact
Jinhua Central Hospital
RECRUITING

Jinhua, China

Contact
Seoul National University Hospital
NOT_YET_RECRUITING

Seoul, South Korea

Contact Phone: •••-•••-•••• Email: •••••@•••••
The Second Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITING

Hangzhou, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Zhejiang Hospital
RECRUITING

Hangzhou, China

Contact
Zhejiang Provincial Hospital of Traditional Chinese Medicine
RECRUITING

Hangzhou, Zhejiang, China

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.